BOSTON, November 11, 2021 / PRNewswire / – Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of its Cell Development Kits (CDK) service. CDKs provide simplified access to the enterprise platform for aspiring cell developers to program cells to meet the greatest challenges facing society. The first CDKs to be launched focused on protein expression programs. The service gives developers access to the toolkit needed to start developing commercial proteins, including prefabricated host cells optimized for protein production, specialized equipment, automation capabilities, genetic engineering expertise , information gathered from Ginkgo’s code base and the applicable infrastructure to design, build and test a custom microbe.
Ginkgo’s CDKs are designed to reduce the cost of initiating a cellular program and speed up development times to create modified microbes, for example, to determine whether a protein can be produced successfully and commercially. The service is also designed to allow clients to prototype their idea in phases, with each phase providing data that can inform the client’s project and business strategy. By simplifying the journey for businesses to start on the Ginkgo platform with standard conditions, a step-by-step approach, low costs – from $ 100,000 for protein expression projects and clear deliverables, CDK can help reduce project risks before large-scale technical development.
âWe believe that engineering biology has enormous potential to revolutionize industries and our customers are using it to develop solutions ranging from alternative dietary proteins and vaccine ingredients to biodegradable plastics and sustainable chemicals,â said Jason kelly, CEO of Ginkgo Bioworks. âBut the biology is still complex and highly variable, making the barrier to entry too high for many product developers who have an idea they want to bring to the world. By providing these researchers, entrepreneurs and dreamers with the resources to achieve their proof of concept, we are able to support the synthetic biology ecosystem to continue to push the boundaries of innovation. ”
If you are a developer interested in learning more about the next batch of CDK projects to launch, approach the Ginkgo team. Ginkgo will also organize a virtual information event, Grow with Ginkgo: you are a cell developer, for potential cell developers who want to learn more about CDK at Thursday November 11 of 10 a.m. to 12 p.m. ET.
About Ginkgo Bioworks
Ginkgo is building a platform to allow customers to program cells as easily as we can program computers. The company’s platform enables biotechnology applications in a variety of markets, from food and agriculture to industrial chemicals and pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and treatment discovery. For more information visit www.ginkgobioworks.com.
Ginkgo Bioworks forward-looking statements
This press release contains certain forward-looking statements within the meaning of federal securities laws, including statements regarding the launch and potential benefits of Ginkgo’s Cell Development Kits (CDK) service and the potential of the Ginkgo platform. Ginkgo cell programming in general. These forward-looking statements are generally identified by the words “believe”, “plan”, “potential”, “expect”, “anticipate”, “estimate”, “intend”, “the strategy”, “the future â,â opportunity, ââ plan â,â may â,â should â,â will â,â would â,â will â,â will continue â,â will probably result â, and similar expressions. Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. There are many factors that could cause actual future events to differ materially from the forward-looking statements contained in this document, including, but not limited to: (i) the effect of the business combination with Soaring Eagle Acquisition Corp. (âSoaring Eagleâ) on Ginkgo’s business relations, performance and the business in general, (ii) the risks that the business combination disrupts Ginkgo’s current plans and potential difficulties in retaining Ginkgo employees, (iii) the outcome of any legal proceedings that may be brought against Ginkgo relating to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo’s securities now that it is a public company due to various factors, including changes in the competitive and highly regulated industries in which Ginkgo plans to operate, variations in performance between competitors, changes in laws and regulations affecting Ginkgo’s business and changes in the structure of the company. combined capital, (v) the ability to implement activities p plans, forecasts and other expectations after the completion of the business combination, and identify and realize additional opportunities, and (vi) the risk of declining demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s current report on Form 8-K filed with the United States Securities and Exchange Commission (the “SEC “) the September 20, 2021 and other documents filed by Ginkgo from time to time with the SEC. These documents identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Ginkgo gives no assurance that it will meet its expectations.
GINKGO BIOWORKS INVESTOR CONTACT:
GINKGO BIOWORKS MEDIA CONTACT:
SOURCE Ginkgo Bioworks